Semaglutide typically lowers fasting glucose and HbA1c levels by 1.01.5% in patients with type 2 diabetes through enhanced insulin secretion and reduced glucagon release
Kazakova TB, Barabanova SV, Novikova NS, Glushikhina MS, Khavinson VKh, Malinin VV, et al

Get exclusive email-only offers and advance notice about sales & events Weekly Ads Savings Center Rebates Coupon Acceptance Policy Price Match Policy Manage Account & Pay Bill Promotions & Offers About the Military Star Card Apply now Express Online Provide Store Feedback Business Delivery Reel Time Movie Guide Gift Card Balance Purchase Gift Cards Home Services Post-Government Employment Exchange Careers Military Retiree Connection Retired Employees Association Equal Employment Opportunity Create Account Authorized Patron Information Contact Us FAQs About My Order Returns & Exchanges Shipping & Delivery Warranties For Overseas Customers Product Recalls & Alerts History and Mission Exchange Quick Facts Exchange by The Numbers Exchange Newsroom Exchange Post Military Exercises & Contingencies Sustainability FOIA/Privacy Doing Business with the Exchange BE FIT Homeschooling School Meal Program The HUB PCS Headquarters Emergency Preparedness Office of Inspector General Commissary Coast Guard Exchange No FEAR Act Notice Site Terms & Conditions Privacy Act Statement

Semaglutide mimics the glucagon-like peptide-1 (GLP-1) hormone that regulates appetite and metabolism in the body, helping patients feel full sooner and for longer, and ultimately promoting weight loss
So first the trial and Im just going to cut and paste from Lillys pressor on this part as to what the trial actually is: TRIUMPH-4 (NCT05869903) is a Phase 3, 68-week, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of retatrutide with placebo in adults with obesity or overweight and knee osteoarthritis